公开(公告)号：US20230099139A1

公开(公告)日：2023-03-30

申请号：US18059765

申请日：2022-11-29

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Mitsuko ISHIHARA ,  Eiichi AKAHOSHI ,  Katsuyuki NAITO ,  Emi NOZAKI ,  Saeko SARUWATARI

IPC: C07D243/08 ,  A61K9/127 ,  C07C229/30 ,  C07D211/14 ,  C07D233/02 ,  C07D241/04

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2  (1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

公开(公告)号：US20240307307A1

公开(公告)日：2024-09-19

申请号：US18468102

申请日：2023-09-15

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Emi NOZAKI ,  Eiichi AKAHOSHI ,  Mitsuko ISHIHARA

IPC: A61K9/127 ,  A61K47/18 ,  A61K47/22 ,  C12N15/88

CPC classification number: A61K9/127 ,  A61K47/18 ,  A61K47/22 ,  C12N15/88

Abstract: According to one embodiment, a lipid composition is for delivering an objective substance to a target cell. The composition is contacted with the target cell under an environment of 37° C. or higher. The composition includes a substance delivery carrier having lipid particle and an objective substance encapsulated in the lipid particle. The lipid particle constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.

公开(公告)号：US20190167812A1

公开(公告)日：2019-06-06

申请号：US16119738

申请日：2018-08-31

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Mitsuko ISHIHARA ,  Eiichi AKAHOSHI ,  Emi NOZAKI

IPC: A61K48/00 ,  C12N15/88 ,  C12N15/113 ,  C07K7/08 ,  A61K9/127 ,  A61K41/00

Abstract: According to one embodiment, a nucleic acid condensing peptide includes one terminal having a first sequence RRRRRR and another terminal having a second sequence RQRQR. Between the first sequence and the second sequence, none or one or more intermediate sequences each consisting of RRRRRR or RQRQR are included. Further, of the first sequence, the second sequence and the intermediate sequences, two or more neutral amino acids are included between any two sequences adjacent to each other.

公开(公告)号：US20230102794A1

公开(公告)日：2023-03-30

申请号：US17930961

申请日：2022-09-09

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Emi NOZAKI ,  Eiichi AKAHOSHI ,  Mitsuko ISHIHARA

IPC: C12N15/10 ,  C12Q1/48 ,  C12N15/85

Abstract: According to one embodiment, a vector set includes a first vector and a second vector. The first vector includes a transposase target sequence, a first promoter sequence ligated to downstream of the transposase target sequence, and a first reporter gene ligated to downstream of the first promoter sequence. The second vector includes a 5′-side transposase recognition sequence, a 3′-side transposase recognition sequence, and a first enhancer sequence arranged therebetween.

公开(公告)号：US20220195401A1

公开(公告)日：2022-06-23

申请号：US17692857

申请日：2022-03-11

Applicant: KABUSHIKI KAISHA TOSHIBA

Inventor： Eiichi AKAHOSHI ,  Emi NOZAKI ,  Mitsuko ISHIHARA

IPC: C12N9/12

Abstract: According to one embodiment, a modified piggyBac transposase polypeptide includes a piggyBac transposase amino acid sequence and a nuclear localization signal amino acid sequence.